According to the FDA’s own summary, 5.3% of infants who received MenQuadfi in clinical trials experienced at least one serious adverse event (SAE)—defined as any medical occurrence resulting in death, hospitalisation or disability
The criteria for a "serious adverse event% is worse than I anticipated.
When the best case scenario is 1 of every 20 infants ends up hospitalized, that's no bueno.
The criteria for a "serious adverse event% is worse than I anticipated.
When the best case scenario is 1 of every 20 infants ends up hospitalized, that's no bueno.